Grifols, ES0171996087

Grifols addressed Canada plasma suspension: Grifols stock sits 18.18 percent below its high

Published on 10/12/2026 at 09:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Net profit rose 28.70 percent to EUR 227 million in the first half of 2026. Grifols stock costs EUR 9.99 on October 12, 2026 versus a EUR 12.21 high.

Key points in brief

Grifols addressed the September 24, 2026 suspension of a Winnipeg plasma collection license.
First-half 2026 revenue reached EUR 3.6 billion and net profit rose 28.70 percent to EUR 227 million.
The stock was at EUR 9.99 at Lang & Schwarz on October 12, 2026, 18.18 percent below its EUR 12.21 52-week high.
Grifols has a November 10, 2026 reporting date listed by TradingView.

Flatlay mit Aktienzertifikat, ISIN-Karte und medizinischen Laborutensilien — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte symbolisiert die Investition in Grifols S.A. ES0171996087 im Biotech-Bereich, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) was trading at EUR 9.99 at Lang & Schwarz on October 12, 2026 at 9:43 a.m. CEST, while its EUR 12.21 52-week high leaves the stock 18.18 percent below that level. According to Reuters on September 24, 2026, Grifols said Health Canada's suspension of a Winnipeg plasma collection license had no impact on ongoing operations.

Three dated operating signals

The chronology shows three measurable developments. On July 28, 2026, Grifols reported first-half revenue of EUR 3.6 billion and net profit of EUR 227 million. On September 16, 2026, the company announced a renewable power agreement covering 40 GWh annually for 10 years, according to MarketScreener. On September 24, 2026, Reuters reported the company response to the Canadian suspension.

What does Canada mean for plasma supply?

CBC News reported that Grifols operates 17 plasma centers in Canada, including two in Winnipeg, and that collection had already been paused before the Taylor Avenue license was suspended. The company said it was working on a reopening plan while retraining staff and strengthening procedures, making regulatory execution a direct operating variable.

First-half figures set the baseline

The first-half 2026 figures provide a stronger operating counterweight. According to Grifols, adjusted EBITDA reached EUR 854 million, up 2.40 percent year over year at constant currency, while the adjusted EBITDA margin was 23.90 percent. Free cash flow before mergers and acquisitions reached EUR 91 million, an improvement of EUR 103 million from the prior-year period. The company also maintained a full-year 2026 free cash flow target of EUR 500 million to EUR 575 million before mergers and acquisitions.

The next dated checkpoint

TradingView lists November 10, 2026 as the next Grifols earnings date. That date gives the market a defined point to assess whether the first-half revenue growth, cash flow improvement and Canadian remediation are progressing together.

Stock stays below its yearly high

Grifols had a market capitalization of EUR 6.8 billion as of October 12, 2026, while its 52-week range stood at EUR 8.43 to EUR 12.21. The stock was trading at EUR 9.99 at Lang & Schwarz on October 12, 2026 at 9:43 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.